Fluicell AB is a Sweden-based company within healthcare industry. It commercializes a product portfolio for processing and studying of individual cells, primarily in the field of drug development. The Companyâ€™s products comprise research tools BioPen and Dynaflow Resolve. Tools enable researchers to study, process and measure drug impact on individual cells. Also, the Company develops bioprinting technology Biopixlar Retina in both two-dimensional (2D) and three-dimensional (3D) options. Biopixlar Retina creates complex tissue-like structures with control over positioning of individual cells.

Employees

Sector

Biotechnology & Medical Research

Calendar

13/11 Earnings release - Q3 2026

More about the company

Quotes

Date	Price	Change	Volume
12/26/12	SEK 27.80	-2.80%	413
11/26/11	SEK 28.60	+4.00%	2,216
10/26/10	SEK 27.50	-0.72%	3,039
09/26/09	SEK 27.70	-1.07%	3,910
06/26/06	SEK 28.00	+7.28%	1,713

Delayed Quote Nasdaq Stockholm

More quotes

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

Delayed Nasdaq Stockholm 02:05:38 12/11/2026 pm IST			5-day change	1st Jan Change
27.80 ^SEK	-2.80%		+6.51%	+178.00%

09/11	Fluicell reaches milestone in cancer collaboration with Ambusol	FW
15/09	Fluicell: Delayed €0.5m receivable settled	FW

Market Cap	3.93Cr 39.37L 35.48L 32.78L 29.64L 56.07L 37Cr 57.45L 1.57Cr 20Cr 1.48Cr 1.45Cr 63Cr	P/E 2024	-1.1x	P/E 2025	-1.65x
Enterprise Value	3.7Cr 37.1L 33.44L 30.89L 27.93L 52.84L 35Cr 54.14L 1.48Cr 19Cr 1.39Cr 1.36Cr 59Cr	EV / Sales 2024	2.04x	EV / Sales 2025	1.91x
Free-Float	78.85%	Yield 2024 *	-	Yield 2025	-

Markets		Quality
Nasdaq Stockholm	FLUI	Delayed
Deutsche Boerse AG	5J90	Delayed
Boerse Muenchen	5J90	Real-time
Börse Stuttgart	5J90	Delayed

09/11	Fluicell reaches milestone in cancer collaboration with Ambusol	FW
15/09	Fluicell: Delayed €0.5m receivable settled	FW
28/08	Fluicell AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
28/08	Fluicell increases revenue and turns to operating profit	FW
08/05	Fluicell reports sharp revenue surge and swings to profit in the first quarter	FW
08/05	Fluicell Q1 net sales up at SEK 6.1 million	RE
08/05	Fluicell AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
07/05	Fluicell nominates AstraZeneca executive to Board of Directors	FW
30/04	Committee proposes Niklas Frisk as Fluicell chairman	RE
30/04	Fluicell proposes new Board of Directors	FW
20/02	Fluicell Narrows Operating Loss in Q4, Final Report Confirms	FW
20/02	Fluicell Q4 net sales SEK 3.8 mln	RE
20/02	Fluicell AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI

Fluicell AB Share Price

Stocks

FLUI

SE0023595459

Biotechnology & Medical Research

Valuation: Fluicell AB

Chart: Fluicell AB

Latest news: Fluicell AB

Press Releases: Fluicell AB

Quotes and Performance

Price Extremes

Managers and Directors: Fluicell AB

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

14/10	Fluicell : at Breakthrough T1D Clinical & Research Congress	PU
02/25/02	Fluicell : and Ambusol enter into exclusive global license and development agreement regarding technology for cancer treatment	PU
22/25/22	Fluicell : receives funding from Breakthrough T1D for collaboration with leading medical university to develop tissue-based type 1 diabetes therapeutics	PU
29/21/29	BioStock: Fluicell partners with big pharma for 3-D bioprinting project	AQ
01/21/01	BioStock: 2021 represents beginning of new era for Fluicell	AQ

1 day	-2.80%
1 week	+6.51%
Current month	-0.36%
1 month	+0.36%
3 months	-4.79%
6 months	-3.47%
Current year	+178.00%

1 week	24.2	29
1 month	23.5	29.4
Current year	7.65	67.2
1 year	7.65	67.2
3 years	7.45	383.6
5 years	7.45	9,625
10 years	7.45	15,330

Manager	Title	Age	Since
Carolina Trkulja CEO	Chief Executive Officer	42	01/01/2023
Gavin Jeffries CTO	Chief Tech/Sci/R&D Officer	46	01/01/2017
Niklas Joakim Wahlberg DFI	Director of Finance/CFO	56	01/07/2023

Director	Title	Age	Since
Daniel T. Chiu BRD	Director/Board Member	54	01/01/2017
Carl Fhager BRD	Director/Board Member	51	01/01/2017
Jan Orwar BRD	Director/Board Member	62	01/01/2015

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
FLUICELL AB	-2.80%	+6.51%	+117.19%	-90.07%	39.37L
WUXI APPTEC CO., LTD.	-1.06%	-0.07%	+60.76%	+68.61%	6.75TCr
ARGENX SE	+1.35%	+8.78%	+14.04%	+92.83%	6.07TCr
LONZA GROUP AG	+0.50%	-0.95%	+20.09%	+98.45%	5.57TCr
BEONE MEDICINES AG	-0.95%	+11.17%	+22.21%	+110.93%	4.8TCr
IQVIA HOLDINGS INC.	-0.23%	+4.07%	+25.63%	+40.08%	4.52TCr
REVOLUTION MEDICINES, INC.	-6.40%	-9.51%	+181.99%	+816.79%	3.91TCr
CELLTRION, INC.	+1.97%	+3.50%	+25.78%	+50.98%	3.53TCr
GENMAB A/S	-0.62%	-2.59%	+80.16%	+56.82%	3.35TCr
INSMED INCORPORATED	+1.05%	+9.77%	-37.66%	+408.42%	2.65TCr
Average	-0.72%	+2.24%	+51.02%	+165.38%	4TCr
Weighted average by Cap.	-0.46%	+1.64%	+43.76%	+168.48%

	2024	2025
Net sales	18.59L 2L 2L 2L 1L 3L 1.75Cr 3L 7L 93.57L 7L 7L 2.98Cr	60.02L 6L 5L 5L 5L 9L 5.64Cr 9L 23.92L 3.02Cr 22.57L 22.09L 9.61Cr
Net income	-1.55Cr -15.54L -14.01L -12.94L -11.7L -22.14L -15Cr -22.68L -61.82L -7.81Cr -58.33L -57.09L -25Cr	-83.32L -8L -8L -7L -6L -11.89L -7.83Cr -12.18L -33.21L -4.19Cr -31.33L -30.67L -13Cr
Net Debt	-1.59Cr -15.96L -14.38L -13.29L -12.01L -22.73L -15Cr -23.29L -63.47L -8.02Cr -59.89L -58.61L -26Cr	-22.62L -2L -2L -2L -2L -3L -2.13Cr -3L -9L -1.14Cr -9L -8L -3.62Cr